Fulgent Genetics, Inc. (FLGT) Q1 Earnings and Revenues Beat Estimates

Group 1: Earnings Performance - Fulgent Genetics reported quarterly earnings of $0.04 per share, exceeding the Zacks Consensus Estimate of a loss of$0.19 per share, representing an earnings surprise of 121.05% [1] - The company has surpassed consensus EPS estimates for four consecutive quarters [2] - The revenue for the quarter ended March 2025 was $73.46 million, surpassing the Zacks Consensus Estimate by 2.76$64.49 million in the same quarter last year [2] Group 2: Stock Performance and Outlook - Fulgent Genetics shares have declined approximately 6.6% since the beginning of the year, while the S&P 500 has decreased by 4.7% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the earnings outlook [4][6] - The current consensus EPS estimate for the upcoming quarter is -$0.19 on revenues of$76.69 million, and for the current fiscal year, it is -$0.66 on revenues of$310.49 million [7] Group 3: Industry Context - The Medical Info Systems industry, to which Fulgent Genetics belongs, is currently ranked in the top 24% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]